1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Chronic Plaque Psoriasis - Pipeline Review, H1 2015

Chronic Plaque Psoriasis - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 109 pages

Chronic Plaque Psoriasis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Chronic Plaque Psoriasis - Pipeline Review, H1 2015’, provides an overview of the Chronic Plaque Psoriasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Plaque Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Plaque Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Plaque Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Plaque Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Chronic Plaque Psoriasis - Pipeline Review, H1 2015
Table of Contents
Introduction 7
Global Markets Direct Report Coverage 7
Chronic Plaque Psoriasis Overview 8
Therapeutics Development 9
Pipeline Products for Chronic Plaque Psoriasis - Overview 9
Pipeline Products for Chronic Plaque Psoriasis - Comparative Analysis 10
Chronic Plaque Psoriasis - Therapeutics under Development by Companies 11
Chronic Plaque Psoriasis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Chronic Plaque Psoriasis - Products under Development by Companies 15
Chronic Plaque Psoriasis - Companies Involved in Therapeutics Development 16
AbGenomics International, Inc. 16
Actelion Ltd 17
Almirall, S.A. 18
ApoPharma Inc. 19
Biotest AG 20
Boehringer Ingelheim GmbH 21
Can-Fite BioPharma Ltd. 22
Coherus BioSciences, Inc. 23
Covagen AG 24
Eli Lilly and Company 25
GlaxoSmithKline plc 26
Mitsubishi Tanabe Pharma Corporation 27
Novartis AG 28
OPKO Health, Inc. 29
Pfizer Inc. 30
Sandoz Inc. 31
Sun Pharmaceutical Industries Inc. 32
Takeda Pharmaceutical Company Limited 33
UCB S.A. 34
XenoPort, Inc. 35
Chronic Plaque Psoriasis - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
AbGn-168H - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
adalimumab biosimilar - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
baricitinib - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
BI-655066 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
certolizumab pegol - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
CF-101 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
CJM-112 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
COVA-322 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
dimethyl fumarate - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
etanercept biosimilar - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
etanercept biosimilar - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
GSK-2831781 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
ixekizumab - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
lunacalcipol - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
MT-1303 - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
namilumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
orilotimod - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
PF-06263276 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
ponesimod - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
tildrakizumab - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
tregalizumab - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
XP-23829 - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
Chronic Plaque Psoriasis - Recent Pipeline Updates 80
Chronic Plaque Psoriasis - Dormant Projects 102
Chronic Plaque Psoriasis - Discontinued Products 103
Chronic Plaque Psoriasis - Product Development Milestones 104
Featured News and Press Releases 104
Jul 16, 2014: Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis 104
Mar 28, 2012: Lilly's Ixekizumab Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis 104
Nov 24, 2011: Biotest Announces Completion Of Phase IIa Trial Of Tregalizumab In Chronic Plaque Psoriasis 106
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 109
Disclaimer 109

List of Tables

Number of Products under Development for Chronic Plaque Psoriasis, H1 2015 9
Number of Products under Development for Chronic Plaque Psoriasis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Chronic Plaque Psoriasis - Pipeline by AbGenomics International, Inc., H1 2015 16
Chronic Plaque Psoriasis - Pipeline by Actelion Ltd, H1 2015 17
Chronic Plaque Psoriasis - Pipeline by Almirall, S.A., H1 2015 18
Chronic Plaque Psoriasis - Pipeline by ApoPharma Inc., H1 2015 19
Chronic Plaque Psoriasis - Pipeline by Biotest AG, H1 2015 20
Chronic Plaque Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H1 2015 21
Chronic Plaque Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H1 2015 22
Chronic Plaque Psoriasis - Pipeline by Coherus BioSciences, Inc., H1 2015 23
Chronic Plaque Psoriasis - Pipeline by Covagen AG, H1 2015 24
Chronic Plaque Psoriasis - Pipeline by Eli Lilly and Company, H1 2015 25
Chronic Plaque Psoriasis - Pipeline by GlaxoSmithKline plc, H1 2015 26
Chronic Plaque Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 27
Chronic Plaque Psoriasis - Pipeline by Novartis AG, H1 2015 28
Chronic Plaque Psoriasis - Pipeline by OPKO Health, Inc., H1 2015 29
Chronic Plaque Psoriasis - Pipeline by Pfizer Inc., H1 2015 30
Chronic Plaque Psoriasis - Pipeline by Sandoz Inc., H1 2015 31
Chronic Plaque Psoriasis - Pipeline by Sun Pharmaceutical Industries Inc., H1 2015 32
Chronic Plaque Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 33
Chronic Plaque Psoriasis - Pipeline by UCB S.A., H1 2015 34
Chronic Plaque Psoriasis - Pipeline by XenoPort, Inc., H1 2015 35
Assessment by Monotherapy Products, H1 2015 36
Number of Products by Stage and Target, H1 2015 38
Number of Products by Stage and Mechanism of Action, H1 2015 40
Number of Products by Stage and Route of Administration, H1 2015 42
Number of Products by Stage and Molecule Type, H1 2015 44
Chronic Plaque Psoriasis Therapeutics - Recent Pipeline Updates, H1 2015 80
Chronic Plaque Psoriasis - Dormant Projects, H1 2015 102
Chronic Plaque Psoriasis - Discontinued Products, H1 2015 103

List of Figures

Number of Products under Development for Chronic Plaque Psoriasis, H1 2015 9
Number of Products under Development for Chronic Plaque Psoriasis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 14
Assessment by Monotherapy Products, H1 2015 36
Number of Products by Top 10 Targets, H1 2015 37
Number of Products by Stage and Top 10 Targets, H1 2015 38
Number of Products by Top 10 Mechanism of Actions, H1 2015 39
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 39
Number of Products by Top 10 Routes of Administration, H1 2015 41
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 42
Number of Products by Top 10 Molecule Types, H1 2015 43
Number of Products by Stage and Top 10 Molecule Types, H1 2015 44

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Radiodermatitis Market: - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Radiodermatitis Market: - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Radiodermatitis, also known as radiation dermatitis, is a significant symptom caused by radiation therapy used in treating cancer as well as exposure to radiation during nuclear disasters. During cance ...

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Eczema - Market Insights, Epidemiology and Market Forecast-2023

Eczema - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Eczema - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.